How common is osteosarcopenic obesity syndrome (OSO) in an adult population?

ISRCTN ISRCTN13557768
DOI https://doi.org/10.1186/ISRCTN13557768
Secondary identifying numbers 254084
Submission date
14/12/2021
Registration date
17/12/2021
Last edited
17/12/2021
Recruitment status
Recruiting
Overall study status
Ongoing
Condition category
Musculoskeletal Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Background and study aims
In the Western world, a growing part of the adult population is overweight and fails to obtain the recommended level of physical activity required to promote and maintain a good health profile. Furthermore, with increasing age, bone decreases combined with reduced muscle mass and increased fat mass. These changes increase the risk of fractures and the ability to maintain daily physical functions. These conditions and/or diagnoses (e.g., obesity, reduced muscle mass, and bone health) have previously been considered as separate conditions. More lately, these whole-body complex changes all originate from hormonal factors and low-grade inflammation processes causing cellular changes in the bone, muscle, and fat tissue. Therefore, the aim of this project is to examine the prevalence of two and three of these conditions in an adult population.

Who can participate?
Adult patients who are overweight.

What does the study involve?
In this project, we will include measurement of bone mineral density, body composition (e.g., percent of muscle- and fat mass), muscle strength, physical activity – and nutrition habits, blood samples to examine inflammatory markers in addition to questioners including well-being, quality of life, work ability and mental health.

What are the possible benefits and risks of participating?
Typically, reduced bone mineral density (e.g., osteoporosis or osteopenia) is detected after a serious fracture. In this project, we will conduct this measurement and provide a status of the participants` bone health which might motivate participants to improve bone health before serious fracture. Still, the conduct these measurements, the participants are exposed to a low dose of radiated radiation. Importantly, the doses are very low and comparable with a 6 hour flight with an aircraft.

Where is the study run from?
The data collection will be conducted in five test locations in Norway (Sogndal, Bergen, Kristiansand, Fredrikstad and Lillehammer).

When is the study starting and how long is it expected to run for?
January 2021 to March 2032

Who is funding the study?
Western Norway University of Applied Sciences
The Research Council of Norway

Who is the main contact?
Prof Atle Saeterbakken, atle.saeterbakken@hvl.no

Contact information

Prof Atle Saeterbakken
Scientific

Røyrgata 6
Sogndal
N-6856
Norway

ORCiD logoORCID ID 0000-0002-5592-6551
Phone +47 (0)57676000
Email atle.saeterbakken@hvl.no

Study information

Study designObservational cross-sectional study
Primary study designObservational
Secondary study designCross sectional study
Study setting(s)Other
Study typeScreening
Participant information sheet Not available in web format, please use the contact details to request a patient information sheet.
Scientific titleOsteosarcopenic obesity syndrome
Study acronymOSO
Study objectives1. Examine the prevalence of having osteosarcopenic obesity syndrome (OSO) (e.g., obesity, sarcopenia, and osteoporosis) among overweight or obese women (e.g., BMI over 25 kg/m²) in Norway
2. Examine the prevalence of having two conditions (sarcopenic obesity and osteopenic obesity) in the same population
3. Examining the age, bone turnover markers, and inflammatory markers as potential moderators and/or risk factors associated with OSO or the dual conditions sarcopenic obesity and osteopenic obesity
4. Examining the well-being, quality of life, work ability, physical activity habits, nutrition habits, muscle strength, muscle quality among individuals with OSO and the dual conditions sarcopenic obesity and osteopenic obesity
Ethics approval(s)Approved 07/05/2021, Norwegian National Research Ethics committees (REK sør-øst C, Gullhaugveien 1-3, 0484 Oslo, Norway; +47 22 84 55 11; rek-sorost@medicin.uio.no), ref. 254084
Health condition(s) or problem(s) studiedOsteosarcopenic obesity syndrome (OSO) (obesity, sarcopenia, and osteoporosis)
InterventionThis project has a cross-sectional design meaning that the participants will only be invited to testing once. Each testing session will last approximately 90 minutes. Overweight (BMI >25 kg/m²) women over 50 years will be recruited from five testing locations (Lillehammer, Kristiansand, Fredrikstad/Sarpsborg, Bergen and Sogndal). Within a 45-minute drive, these locations include close to 20% of the Norwegian population. All test locations are related to University Colleges and will involve researchers, students and participants from a broad area of Norway.

DEXA is the gold standard to examine bone mass and bone mineral density in addition to measuring lean mass and body fat. Furthermore, the study will include measurements of muscle strength as sarcopenia causes reduced muscle strength, muscle mass and reduced physical performance (gait speed, handgrip strength, one-leg stance, and sit-to-stand chair). Reduced muscle strength and physical performance increase the risk of falls and fractures. Questionnaires including well-being, quality of life, work ability, mental health, physical activity habits, and nutrition habits (RAND-36, PROS, PROQOL, IPAQ- IPAQ, and SarQoL) will be included as these outcomes are often overlooked in epidemiology studies. The questionnaires will provide a broader and more in-depth understanding of how these individuals experience the conditions. Furthermore, to gain greater knowledge of the fat infiltration of the muscles, sub-groups will be invited to undergo magnetic resonance imaging (MRI) of the quadriceps to examine muscle quality (muscle volume divided by the muscle force output) and degree of fat infiltration in the muscle. Accordingly, a subpopulation of the participants will be enrolled in analyses of biomarkers of inflammation and bone turnover using blood samples. In addition to 3000 women being enrolled in this project, the researchers aim to use register data from the HUNT study (n = 22,857), the Tromsø Study (n = 3,100) and 100,000 from the UK biobank which all includes adults with DEXA in addition to as many of the outcomes as described above as possible. By including register data from both sexes, will be able estimate the prevalence of OSO in a Norwegian population and a comparable population in the UK.
Intervention typeMixed
Primary outcome measureBone mineral density, lean mass, and body fat measured using DEXA at a single time point
Secondary outcome measuresMeasured at a single time point:
1. Muscle strength in isometric knee extension and grip strength
2. Muscle mass measured using DEXA
3. Physical performance (gait speed, handgrip strength, one-leg stance, and sit-to-stand chair)
4. Well-being, quality of life, work ability, mental health, physical activity habits, and nutrition habits (RAND-36, PROS, PROQOL, IPAQ- IPAQ, and SarQoL)
5. Muscle quality (muscle volume divided by the muscle force output) and degree of fat infiltration in the muscle measured using magnetic resonance imaging (MRI) of the quadriceps
5. Biomarkers of inflammation and bone turnover measured using blood samples
Overall study start date01/01/2021
Completion date01/03/2032

Eligibility

Participant type(s)Healthy volunteer
Age groupAdult
Lower age limit50 Years
SexBoth
Target number of participants25,000 - 125,000
Key inclusion criteria1. Overweight (BMI >25 kg/m²) women over 50 years
2. All adults (independent of age or sex) will be included from the biobank databases
Key exclusion criteriaAged under 18 years
Date of first enrolment01/05/2022
Date of final enrolment01/05/2030

Locations

Countries of recruitment

  • Norway

Study participating centre

Western Norway University of Applied Sciences
Røyrgata 6
Sogndal
N-6856
Norway

Sponsor information

Western Norway University of Applied Sciences
University/education

Røyrgata 6
Sogndal
N-6856
Norway

Phone +47 (0)57676000
Email post@hvl.no
Website https://www.hvl.no
ROR logo "ROR" https://ror.org/05phns765

Funders

Funder type

University/education

Høgskulen på Vestlandet
Government organisation / Universities (academic only)
Alternative name(s)
Western Norway University of Applied Sciences, HVL
Location
Norway

Results and Publications

Intention to publish date01/01/2024
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryStored in non-publicly available repository, Not expected to be made available
Publication and dissemination planThe researchers will publish the results in international scientific high-quality peer-reviewed open access journals and present the results at national and international scientific conferences. They will share the information and results with health professionals and the national Ministry of Health and Care Services in order for them to utilize the evidence-based knowledge in future programming decisions. The researchers will make the knowledge gained from the results available also through chronicles, media interviews, regional conferences and meetings with the stakeholders. Finally, popular lectures will be held for local units and associations (e.g., pensioners ‘associations, Nasjonalforeningen for Folkehelse, Norske Kvinners Sanitetsforening, osteoporosis associations) involved and contributing to recruiting potential participants. Furthermore, the findings will be used the international collaborations including comparisons of countries adopting the same outcome measures.
IPD sharing planThe datasets generated during and/or analysed during the current study will be stored in a non-publically available repository.

All data will be stored on Western Norway University of Applied Sciences (HVL) research servers. The participants‘ data will not be stored by name, but with an identification code to ensure anonymity. The connection key between the participants and identification code will be stored separately according to the current rules of storage of personal information in research. All participants can ask for insight into which variables are stored.

Western Norway University of Applied Sciences research servers are restricted to Norwegian laws and regulations and the Western Norway University of Applied Sciences regulations. To gain access to the data sets or available data, the Western Norway University of Applied Sciences are working with Norwegian authorities to establish legal procedures and regulation. At the present point, the solution is not completed. Therefore, please use this contact information atle.saeterbakken@hvl.no to gain an update on the process.

Editorial Notes

17/12/2021: Trial's existence confirmed by Norwegian National Research Ethics committee.